Japan's New Cannabis Law Reshapes the CBD Import Market
Photo via Pexels.
For decades, Japan regulated cannabis according to a distinction that made sense for hemp farmers in 1948 and almost no sense for anyone selling CBD oil in 2023: which part of the plant a product came from. Flowers and leaves were controlled. Stalks and seeds were not, regardless of what was actually in them. That law, the Cannabis Control Law, was drafted under American occupation authorities and left essentially untouched for decades while the rest of the world built an entirely new commercial category around cannabidiol. On December 12, 2024, Japan finally rewrote the thing structurally, not cosmetically.
The headline change sounds like loosening: Japan swapped its plant-part system for an ingredient-based model that regulates finished products by how much THC they actually contain, rather than which part of the cannabis plant they were extracted from. That is a framework built for a CBD retail shelf, not a hemp field. But anyone tempted to read this as Japan going soft on cannabis should look at what came bundled with it. The same reform package criminalized cannabis use itself for the first time in the country's history, a gap that had technically existed even in one of Asia's stricter drug regimes. And barely a year later, regulators moved just as fast in the other direction, designating the minor cannabinoid CBN a controlled substance on a timeline measured in months. For importers and foreign CBD brands eyeing Japan, the practical result isn't a wider opening. It's a narrower, far more rigorously tested lane than the one that existed before.
From Plant-Part to Ingredient-Based: What Actually Changed
To understand why this reform mattered, you have to understand how oddly the old law was built. The 1948 Cannabis Control Law drew its line at the plant itself: mature stalks and seeds were carved out as exempt material, full stop, no matter what cannabinoids ended up concentrated in an extract made from them. Flowers and leaves, meanwhile, were controlled regardless of their actual THC content. It was a structure designed around traditional hemp agriculture -- fiber from stalks, oil and food from seeds -- decades before anyone was isolating cannabinoids at scale.
That mismatch became untenable once CBD extraction went global. Companies routinely marketed stalk- and seed-derived CBD products as compliant by definition, while regulators had no clean, scientifically defensible way to check whether a given extract's THC level actually warranted concern. It was a loophole built on ambiguity rather than real safety analysis, and customs officials inherited the headache of enforcing it.
The Diet passed amendments addressing this in late 2023, and they took effect December 12, 2024, alongside parallel revisions to the Narcotics and Psychotropic Substances Control Law. The new model drops plant-part distinctions entirely and regulates based on measured THC content in the finished product -- the oil, the gummy, the vape cartridge -- not its botanical origin. That gives customs inspectors and retailers a testable, repeatable standard instead of a definitional argument. Notably, the provisions governing licensed industrial and research cultivation were left largely intact, so Japan's small but longstanding hemp-fiber and hemp-seed sector continues operating under its existing separate licensing structure.
The New THC Thresholds: Why Full-Spectrum CBD Is Mostly Dead in Japan
Japan sets vastly different residual THC limits depending on CBD product type, allowing up to 10 mg/kg in oils and powders but only 1 mg/kg in solids and a strict 0.1 mg/kg in beverages—a 100-fold difference between the most and least permissive categories.
Here's where the reform gets genuinely restrictive, and where a lot of foreign brands are going to get burned if they haven't checked the numbers. Japan's new residual THC limits are tiered by product category, and they're tight by international standards: 10 mg/kg (10 ppm) for oils and powders, 1 mg/kg for solids such as edibles and vape cartridges, and just 0.1 mg/kg for beverages. Compare that to the 0.3% dry-weight threshold common in US hemp law, and the gap becomes obvious -- Japan's beverage limit alone is roughly 3,000 times stricter than the American hemp standard on a comparable basis.
Crossing these thresholds isn't treated as a labeling or compliance infraction. A product that tests over the limit is legally reclassified as a narcotic under Japanese law, which changes everything about how it's handled -- seizure, prosecution exposure, the works. Regulators also closed off a cannabinoid-chemistry workaround: THCA, the non-psychoactive acidic precursor that converts to active THC when heated, is explicitly banned rather than treated as exempt simply because it isn't intoxicating in its raw form. That closes the same kind of loophole logic that let stalk-derived products slide under the old law.
The practical fallout is visible in compliance data coming out of Japanese import testing labs: full-spectrum CBD oils, which by definition carry trace amounts of multiple cannabinoids including THC, are failing these limits as a matter of routine rather than exception. That's pushed the compliant Japanese market decisively toward isolates and broad-spectrum formulations, where THC has been removed or never existed in the first place. Foreign brands built around full-spectrum entourage-effect marketing have had to either reformulate specifically for Japan or exit the market, because the old margin for trace THC simply doesn't exist here anymore.
A New Crime: Japan Criminalizes Cannabis Use Itself
Photo by QuinceCreative via Pixabay.
The part of this reform that got far less international coverage than the CBD rules is arguably more consequential for anyone physically in Japan: cannabis use became a standalone criminal offense for the first time in the country's postwar history. Under the old law, prosecutors could go after possession, cultivation, or distribution, but using cannabis wasn't itself codified as a distinct crime -- an odd gap that the revised law closes directly.
The penalty structure is specific and tiered. Use, possession, transfer, and receipt of cannabis each carry prison terms of up to seven years. Offenses committed for profit carry heavier exposure -- one to ten years' imprisonment plus fines of up to JPY 3 million. Unlicensed cultivation, import, and export fall into that same one-to-ten-year range. These aren't suggested guidelines; they're statutory maximums written into a legal system that tends to apply its drug laws with little prosecutorial discretion compared to jurisdictions that favor diversion or treatment-first approaches.
What makes this worth sitting with is the sequencing. Japan didn't trade stricter personal-use enforcement for a more open CBD market, or vice versa -- it did both at once, in the same legislative package. The commercial lane for compliant CBD and cannabis-derived medicine opened precisely as the personal-use lane tightened into something more punitive than before. That's consistent with how Japan has historically approached drug policy generally: tightly codified statutes, clearly defined thresholds, and enforcement that leaves little room for ambiguity or case-by-case leniency. Travelers and residents alike should treat the 2024 reform as a hardening of personal-use risk, not a softening, regardless of what's happening on the commercial CBD shelf.
The Medical Door Opens: Epidiolex and MHLW's Pharmaceutical Pathway
Photo via Pexels.
Buried inside the same amendment that tightened personal-use law is a genuinely new medical pathway that didn't exist in Japan before. The revision stripped out clauses that had blanket-prohibited medicinal use, manufacture, and possession of cannabis-derived substances outright -- language that had made it legally impossible to pursue cannabis-based pharmaceuticals in Japan regardless of clinical evidence elsewhere.
The clearest beneficiary of that change is Epidiolex, the purified CBD-based epilepsy medication already approved by regulators elsewhere, including across the EU. It's now moving through the Ministry of Health, Labour and Welfare's pharmaceutical review process, which is the only route available -- this is a formal drug-approval pathway, not the kind of broader medical cannabis program that patients in Germany, Canada, or several other jurisdictions can access through physician certification. There's no equivalent in Japan to a medical cannabis card or dispensary system. A product has to clear MHLW as a licensed pharmaceutical, full stop, which is a slower and narrower road but one with a real endpoint now that the blanket prohibition is gone.
On the industrial and research side, the framework left intact by the reform is already producing results. In 2025, Japan issued its first cultivation license under the revised structure -- a Class 1 cannabis cultivator license granted in Fukushima Prefecture. That license matters less for its immediate output than for what it demonstrates: the licensing apparatus for legitimate industrial and research cultivation is operational, not theoretical, under the new law. Between the Fukushima license and the Epidiolex review moving through MHLW, Japan now has two live, trackable signals of how far its post-reform system is actually willing to go -- one on the cultivation side, one on the pharmaceutical side -- rather than just a statute sitting on paper.
2026's CBN Ban and What It Signals for Importers
If anyone doubted how quickly Japanese regulators would move once a new cannabinoid drew their attention, 2026 answered that question. On October 28, 2025, a Pharmaceutical Affairs Council subcommittee concluded there was a high probability of psychoactive toxicity and associated health risk from cannabinol, or CBN -- a minor cannabinoid that had been showing up in sleep-aid and relaxation products as brands looked for ways to differentiate once THC and THCA got locked down. MHLW acted on that finding fast: a ministerial ordinance published March 18, 2026 designated CBN a shitei yakubutsu, a designated controlled substance, with enforcement starting June 1, 2026.
That's roughly a seven-month gap between the advisory finding and a hard legal deadline -- not the multi-year rulemaking timelines importers might be used to elsewhere. Once enforcement begins, manufacture, import, sale, possession, and use of CBN products are prohibited outright, with narrow exceptions carved out for existing patients. Violators face up to three years' imprisonment or fines as high as 3 million yen. Japanese retailers felt the deadline immediately -- Naturecan, CelaPhia, Chillaxy, and Rounwellness all issued stock liquidation notices through April and May 2026, clearing CBN inventory before it became unsellable and, soon after, illegal to hold.
The CBN episode is a template, not an isolated event. It shows MHLW is willing to add newly popular minor cannabinoids to the controlled list on short notice the moment novel products built around them start appearing on retail shelves. For importers, the operational upshot has been a real tightening of documentation requirements: a Certificate of Manufacture and a laboratory Component Analysis Report are now expected before customs clearance, and both border inspection and retail-level compliance checks have intensified noticeably through 2026. Anyone shipping cannabinoid products into Japan now needs to treat every batch as something regulators might scrutinize down to the compound level, not just the THC line.
Strip away the framing and what Japan actually did in December 2024 wasn't legalize CBD -- it built, for the first time, a legal category precise enough for CBD to exist inside at all. That category comes with THC tolerances tighter than almost anywhere else in Asia, a brand-new criminal statute for personal use, and a regulatory apparatus that has already shown it can add a newly popular cannabinoid to the controlled list within months of flagging it as a concern.
Foreign brands that treat Japan as just another CBD export market -- shipping the same full-spectrum formulations that clear customs elsewhere -- are going to keep failing at the border or getting pulled from shelves after the fact. The CBN rollout made the lesson explicit: a Certificate of Manufacture and an independent lab Component Analysis Report aren't paperwork formalities here, they're the difference between a cleared shipment and a seized one. Isolate-grade documentation, batch-level testing, and a willingness to reformulate specifically for Japan's thresholds aren't optional extras for this market; they're the baseline cost of entry.
The thing worth actually watching going forward is MHLW's pharmaceutical review of Epidiolex. If that drug clears Japan's approval process, it will be the clearest real-world evidence yet of how far regulators are willing to let cannabis-derived medicine travel beyond the narrow, heavily policed CBD lane they've just finished building. Everything else -- the Fukushima cultivation license, the CBN ban, the new THC thresholds -- tells you Japan is tightening and formalizing. Epidiolex's path through MHLW will tell you whether there's any real ceiling above that, or whether the ceiling is exactly where it looks right now.
